CDK9-IN-15

CAS No. 852678-17-2

CDK9-IN-15( —— )

Catalog No. M35446 CAS No. 852678-17-2

CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 62 In Stock
5MG 92 In Stock
10MG 155 In Stock
25MG 296 In Stock
50MG 440 In Stock
100MG 619 In Stock
500MG 1278 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDK9-IN-15
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.
  • Description
    CDK9-IN-15 (compound 50) is a potent CDK9 inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    852678-17-2
  • Formula Weight
    293.34
  • Molecular Formula
    C16H11N3OS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (426.13 mM; Ultrasonic )
  • SMILES
    Oc1cccc2c(Nc3ncnc4sccc34)cccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Van Duyne R, et al. Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription. J Mol Biol. 2013;425(4):812-829.?
molnova catalog
related products
  • Avotaciclib

    Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.

  • Cirtuvivint

    Cirtuvivint (SM08502) is a potent, orally active CDC-like kinase (CLK) inhibitor useful for the study of arthritis.

  • Cdc7-IN-5

    Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase. Cdc7, a serine-threonine protein kinase enzyme, is essential for the initiation of DNA replication in the cell cycle.